LSD1とWNTの転写を混乱させ,AMLの分化をシネジスティックに誘導する
Amir Hosseini1, Abhinav Dhall2, Nemo Ikonen3
1Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nature
|April 16, 2025
まとめ
この研究では,LSD1抑制とGSK3抑制を併用することで,細胞の分化を促進し,マウスの生存率を向上させることで,急性骨髄性白血病 (AML) を効果的に治療することが示されました.
科学分野:
- 腫瘍学
- 分子生物学
- ガン治療薬
背景:
- 細胞分化障害は 骨髄性悪性腫瘍の重要な特徴です
- ATRAやATOのような薬剤を用いた差別化治療は,急性プロミエロサイト性白血病において有効であるが,AMLにおけるより広範な適用性は不明である.
研究 の 目的:
- 急性骨髄性白血病 (AML) のLSD1阻害 (LSD1i) とGSK3キナーゼ阻害 (GSK3i) の併用による治療の可能性を調査する.
- この組み合わせ療法で治療されたAML細胞の分化を誘発する基礎的分子機構を解明する.
主な方法:
- 既定のAML細胞系とヒトのAML細胞を同時にLSD1iとGSK3iで治療する.
- 患者から派生した異種移植マウスモデルにおける治療的差異化,腫瘍負担,生存の評価.
- 遺伝子発現分析,転写因子誘導 (IRF7,β-カタニン),経路分析 (I型インターフェロン,WNT経路) を含むメカニズム研究.
主要な成果:
- LSD1iとGSK3iの組み合わせは,AML細胞の治療的分化を強力に促進しました.
- この組み合わせは,腫瘍の負荷を軽減し,臨床前AMLマウスモデルで生存期間を大幅に延長しました.
- メカニズム的に,治療はタイプIインターフェロン経路を活性化し,プロ腫瘍性WNTシグナル伝達と細胞サイクル遺伝子を抑制しました.
結論:
- LSD1とGSK3の同時抑制は,AMLに対する有望な治療戦略です.
- 組み合わせ治療は,転写プログラムを再構成して,幹を抑制し,差別化を促進し,他のWNT駆動がんに潜在的な影響を及ぼします.
関連する概念動画
Canonical Wnt Signaling Pathway
8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
Non-Canonical Wnt Signaling Pathways
7.3K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Forced Transdifferentiation
1.9K
Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial...
Artificial...
1.9K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K


